Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Plummer

Showing results (31-40 of 161) with videos related to

Pageof 17
Sort By:
Journal of the American Academy of Dermatology|November 22, 2024
A multivariable disease-specific model enhances prognostication beyond current Merkel cell carcinoma staging: An international cohort study of 10,958 patientsTom W Andrew, Sophie Erdmann, Mogdad Alrawi, et al.
NPJ Digital Medicine|January 8, 2025
A hybrid machine learning approach for the personalized prognostication of aggressive skin cancersTom W Andrew, Mogdad Alrawi, Ruth Plummer, et al.
British Journal of Cancer|September 29, 2020
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumoursMalaka Ameratunga, Irene Braña, Petri Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesRuth Plummer, Penella Woll, David Fyfe, et al.
Anti-Cancer Drugs|March 19, 2014
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancerHilary Calvert, Chris Twelves, Malcolm Ranson, et al.
Science Signaling|May 26, 2011
Progress in the function and regulation of ADP-RibosylationMichael O Hottiger, Mark Boothby, Friedrich Koch-Nolte, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Experimental Hematology & Oncology|October 14, 2017
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 studyJennifer Brown, Ruth Plummer, Todd M Bauer, et al.
Gynecologic Oncology|October 18, 2011
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancerAhmed Elattar, Katharine G Warburton, Asima Mukhopadhyay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesotheliomaAndy Hughes, Paula Calvert, Ashraf Azzabi, et al.
Pageof 17

Showing results (31-40 of 161) with videos related to

Sort By:
Pageof 17
Journal of the American Academy of Dermatology|November 22, 2024
A multivariable disease-specific model enhances prognostication beyond current Merkel cell carcinoma staging: An international cohort study of 10,958 patientsTom W Andrew, Sophie Erdmann, Mogdad Alrawi, et al.
NPJ Digital Medicine|January 8, 2025
A hybrid machine learning approach for the personalized prognostication of aggressive skin cancersTom W Andrew, Mogdad Alrawi, Ruth Plummer, et al.
British Journal of Cancer|September 29, 2020
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumoursMalaka Ameratunga, Irene Braña, Petri Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesRuth Plummer, Penella Woll, David Fyfe, et al.
Anti-Cancer Drugs|March 19, 2014
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancerHilary Calvert, Chris Twelves, Malcolm Ranson, et al.
Science Signaling|May 26, 2011
Progress in the function and regulation of ADP-RibosylationMichael O Hottiger, Mark Boothby, Friedrich Koch-Nolte, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Experimental Hematology & Oncology|October 14, 2017
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 studyJennifer Brown, Ruth Plummer, Todd M Bauer, et al.
Gynecologic Oncology|October 18, 2011
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancerAhmed Elattar, Katharine G Warburton, Asima Mukhopadhyay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesotheliomaAndy Hughes, Paula Calvert, Ashraf Azzabi, et al.
Pageof 17